371 related articles for article (PubMed ID: 28823521)
1. The potential and promise of IL-15 in immuno-oncogenic therapies.
Robinson TO; Schluns KS
Immunol Lett; 2017 Oct; 190():159-168. PubMed ID: 28823521
[TBL] [Abstract][Full Text] [Related]
2. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
[TBL] [Abstract][Full Text] [Related]
3. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
Stoklasek TA; Schluns KS; Lefrançois L
J Immunol; 2006 Nov; 177(9):6072-80. PubMed ID: 17056533
[TBL] [Abstract][Full Text] [Related]
4. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation.
Van den Bergh JM; Lion E; Van Tendeloo VF; Smits EL
Pharmacol Ther; 2017 Feb; 170():73-79. PubMed ID: 27777088
[TBL] [Abstract][Full Text] [Related]
5. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
6. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
7. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 15 as a promising candidate for tumor immunotherapy.
Jakobisiak M; Golab J; Lasek W
Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164
[TBL] [Abstract][Full Text] [Related]
9. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
Zhang S; Zhao J; Bai X; Handley M; Shan F
Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-15: new kid on the block for antitumor combination therapy.
Van den Bergh JM; Van Tendeloo VF; Smits EL
Cytokine Growth Factor Rev; 2015 Feb; 26(1):15-24. PubMed ID: 25306466
[TBL] [Abstract][Full Text] [Related]
11. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.
Fujii R; Jochems C; Tritsch SR; Wong HC; Schlom J; Hodge JW
Cancer Immunol Immunother; 2018 Apr; 67(4):675-689. PubMed ID: 29392336
[TBL] [Abstract][Full Text] [Related]
12. Enhancing Natural Killer and CD8
Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
[TBL] [Abstract][Full Text] [Related]
13. IL-15: targeting CD8+ T cells for immunotherapy.
Diab A; Cohen AD; Alpdogan O; Perales MA
Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 biology and its therapeutic implications in cancer.
Steel JC; Waldmann TA; Morris JC
Trends Pharmacol Sci; 2012 Jan; 33(1):35-41. PubMed ID: 22032984
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W
Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573
[TBL] [Abstract][Full Text] [Related]
16. IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract][Full Text] [Related]
17. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
[TBL] [Abstract][Full Text] [Related]
18. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.
Ochoa MC; Fioravanti J; Rodriguez I; Hervas-Stubbs S; Azpilikueta A; Mazzolini G; Gúrpide A; Prieto J; Pardo J; Berraondo P; Melero I
Cancer Res; 2013 Jan; 73(1):139-49. PubMed ID: 23149919
[TBL] [Abstract][Full Text] [Related]
19. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis.
Burkett PR; Koka R; Chien M; Chai S; Boone DL; Ma A
J Exp Med; 2004 Oct; 200(7):825-34. PubMed ID: 15452177
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]